Cyclic GMP-AMP Displays Mucosal Adjuvant Activity in Mice.

Skrnjug, Ivana; Guzmán, Carlos Alberto; Ruecker, Christine

dc.contributor.author	Skrnjug, Ivana
dc.contributor.author	Guzmán, Carlos Alberto
dc.contributor.author	Ruecker, Christine
dc.date.accessioned	2014-10-17T08:20:49Z
dc.date.available	2014-10-17T08:20:49Z
dc.date.issued	2014
dc.identifier.citation	Cyclic GMP-AMP Displays Mucosal Adjuvant Activity in Mice. 2014, 9 (10):e110150 PLoS ONE	en
dc.identifier.issn	1932-6203
dc.identifier.pmid	25295996
dc.identifier.doi	10.1371/journal.pone.0110150
dc.identifier.uri	http://hdl.handle.net/10033/332841
dc.description.abstract	The recently discovered mammalian enzyme cyclic GMP-AMP synthase produces cyclic GMP-AMP (cGAMP) after being activated by pathogen-derived cytosolic double stranded DNA. The product can stimulate STING-dependent interferon type I signaling. Here, we explore the efficacy of cGAMP as a mucosal adjuvant in mice. We show that cGAMP can enhance the adaptive immune response to the model antigen ovalbumin. It promotes antigen specific IgG and a balanced Th1/Th2 lymphocyte response in immunized mice. A characteristic of the cGAMP-induced immune response is the slightly reduced induction of interleukin-17 as a hallmark of Th17 activity - a distinct feature that is not observed with other cyclic di-nucleotide adjuvants. We further characterize the innate immune stimulation activity in vitro on murine bone marrow-derived dendritic cells and human dendritic cells. The observed results suggest the consideration of cGAMP as a candidate mucosal adjuvant for human vaccines.
dc.language.iso	en	en
dc.rights	Archived with thanks to PloS one	en
dc.title	Cyclic GMP-AMP Displays Mucosal Adjuvant Activity in Mice.	en
dc.type	Article	en
dc.contributor.department	Helmholtz Cente for infection research,Inhoffenstr. 7, D38124 Braunschweig, Germany.	en
dc.identifier.journal	PloS one	en
refterms.dateFOA	2018-06-12T19:58:07Z
html.description.abstract	The recently discovered mammalian enzyme cyclic GMP-AMP synthase produces cyclic GMP-AMP (cGAMP) after being activated by pathogen-derived cytosolic double stranded DNA. The product can stimulate STING-dependent interferon type I signaling. Here, we explore the efficacy of cGAMP as a mucosal adjuvant in mice. We show that cGAMP can enhance the adaptive immune response to the model antigen ovalbumin. It promotes antigen specific IgG and a balanced Th1/Th2 lymphocyte response in immunized mice. A characteristic of the cGAMP-induced immune response is the slightly reduced induction of interleukin-17 as a hallmark of Th17 activity - a distinct feature that is not observed with other cyclic di-nucleotide adjuvants. We further characterize the innate immune stimulation activity in vitro on murine bone marrow-derived dendritic cells and human dendritic cells. The observed results suggest the consideration of cGAMP as a candidate mucosal adjuvant for human vaccines.